Advertisements

Flohale (Fluticasone)

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Flohale (Fluticasone)

Quick Facts

Property Description
Active ingredient Fluticasone Propionate
Form Inhalation Aerosol / Powder / Suspension
Pharmacological class Corticosteroid (Glucocorticoid)
Common use Long-term prophylaxis and management of airway inflammation
Origin Synthetic, Trifluorinated Derivative

What Type of Medicine is Flohale (Fluticasone)?

Flohale is a medicine containing the active ingredient Fluticasone Propionate, which is officially categorized as a potent synthetic glucocorticoid belonging to the broader class of corticosteroids. This substance is structurally and functionally similar to the natural hormones produced by the body, but it is chemically manufactured as a trifluorinated derivative specifically for targeted therapeutic application. Its primary action is founded on its high affinity and selective agonist action on the intracellular glucocorticoid receptor. This local mechanism supports its role as a necessary prescription-only controller agent (Rx status).

The classification of Fluticasone Propionate establishes its clinical role in controlling chronic conditions rather than providing immediate relief for acute, sudden symptoms. It is often supplied in distinct dosage forms, such as Respules (nebulizer suspensions) or metered-dose inhalers, offering variations for different patient groups, including adults and children.

What is the Form and General Purpose of Fluticasone Propionate?

Fluticasone Propionate is formulated as a single-active-ingredient product (monotherapy) delivered exclusively via the inhaled route of administration. The drug is supplied in specialized dosage forms for oral inhalation, which typically include an inhalation aerosol, an inhalation powder, or a nebulizer suspension. The inhaled delivery system ensures that the therapeutic effects are maximized locally while minimizing systemic exposure.

The general purpose of this medicine is to act as a powerful, localized anti-inflammatory agent for prophylaxis and long-term management. By suppressing the local release of inflammatory mediators and reducing swelling within the airways, the drug prevents chronic irritation and helps maintain stable, open breathing passages.

Advertisements

What side effects are possible with Flohale (Fluticasone)?

Adverse Effects and Safety Information

Fluticasone (Flohale) is associated with both common local side effects and the potential for serious systemic effects, particularly with prolonged use or high doses, as documented in regulatory guidelines.

Common and Localized Reactions

Side effects reported as common (occurring in more than 1 in 100 people) primarily involve the local application area. These include epistaxis (nosebleeds), headache, nasal irritation/burning, and sore throat or pharyngitis. Localized infections with Candida albicans (thrush) in the mouth or throat may also occur and may require specific treatment and temporary discontinuation.

Serious and Clinically Significant Risks

Fluticasone carries warnings for several serious adverse reactions:

  • Systemic Corticosteroid Effects: These are rare but can include adrenal suppression (HPA axis suppression), Cushing's syndrome features, and growth reduction in children. The risk increases with higher doses and prolonged exposure.
  • Ocular Effects: The development of glaucoma (increased intraocular pressure) and cataracts has been reported with long-term intranasal and inhaled corticosteroid use. Regular eye examinations may be warranted for long-term users.
  • Hypersensitivity: Rare, but severe allergic reactions have been documented, including anaphylaxis, angioedema, rash, and urticaria.
  • Nasal Septal Perforation (a hole in the septum) is a rare but documented adverse reaction.

Safety Restrictions and Precautions

Caution is advised in specific populations and clinical situations:

  • Immunosuppression: Fluticasone can suppress the immune system, potentially worsening existing infections, such as tuberculosis, systemic fungal, bacterial, viral, or parasitic infections, or ocular herpes simplex. Use in these patients requires careful monitoring.
  • Wound Healing: Use is not recommended in patients with recent nasal surgery, nasal trauma, or unhealed nasal ulcers due to the potential for impaired wound healing.
  • Pediatric Use: Children using fluticasone should be regularly monitored for potential growth retardation to ensure the lowest effective dose is being used.

Regulatory warnings emphasize that close monitoring is necessary to detect signs of systemic effects, local infections, and ocular changes during long-term treatment.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose Profile

Acute Overdose

Acute overdose from the inhaled form of Fluticasone alone is generally considered unlikely to cause immediate clinical harm due to the medication's low systemic absorption. Urgent action beyond observation is typically not required in isolation.

Chronic Overdose

Chronic use of doses higher than those recommended, or use in individuals who are particularly susceptible, may lead to systemic corticosteroid effects. These effects primarily involve the endocrine system and include hypercorticism (signs of excess cortisol) and adrenal suppression (suppression of the hypothalamic-pituitary-adrenal or HPA axis).

Signs of chronic systemic overexposure may include symptoms of adrenal insufficiency, such as unusual weakness, fatigue, loss of appetite, or darkening of the skin, and may necessitate slow discontinuation under professional guidance.

When to Seek Medical Attention

Condition
Signs of Serious Systemic Effects If changes indicating hypercorticism or adrenal suppression (HPA axis suppression) occur, contact a healthcare provider immediately. This may require medical management to slowly taper the medication.
Co-existing Stress Individuals who have recently stopped or reduced systemic corticosteroids and are using Fluticasone must be closely monitored for acute adrenal insufficiency during periods of stress, such as surgery, infection, or trauma.
General Emergency If a person experiences severe symptoms such as collapsing, trouble breathing, chest pain, or seizures, immediately call emergency medical services. Always contact a poison control center for guidance in any suspected overdose situation.
Advertisements

Therapeutic Uses of Flohale (Fluticasone)

What Flohale (Fluticasone) Treats: Main Uses and Benefits

Therapeutic Role

The primary therapeutic role of inhaled Fluticasone Propionate (Flohale) is commonly used to act as a controller medication for the long-term management of chronic airway diseases. It is applied across domains that require continuous, preventative support to reduce the burden of persistent symptoms related to inflammatory or irritative states.

Conditions and Symptom Management

This medicine is used as a controller medication in the daily, prophylactic management of persistent asthma in adults and children. It is also considered relevant in the maintenance treatment of COPD, including conditions like chronic bronchitis. The medication is applied in addressing symptom clusters related to physical discomfort, such as frequent wheezing, chronic coughing, and chest tightness.

The daily application supports the stabilization of the airways. This therapeutic stability may assist with reducing the frequency of acute episodes or flare-ups, which contributes to easing the overall symptom load. The strategy may assist with maintaining functional stability, which can support the patient during difficult episodes by easing distress and contributes to reducing the reliance on frequent use of fast-acting rescue medications or systemic oral corticosteroids.


Quick Fact: Relief for Symptoms that interfere with daily functioning

Regulatory References

  1. NIH MedlinePlus Drug Information
Advertisements

Eligibility and Restrictions for Use

Who can and cannot use Flohale (Fluticasone)?

Official regulatory documents define the strict population boundaries for the use of Flohale (Fluticasone Propionate), focusing on patient eligibility rather than clinical advice.

Contraindicated Use

Use is contraindicated in patients with a known severe hypersensitivity to Fluticasone or any product component. The medicine must not be used for the primary treatment of status asthmaticus or any other acute episode of asthma requiring immediate intensive care.

Age and Developmental Eligibility

The medicine is approved for adults and adolescents (aged 12 years and older) for asthma and rhinitis maintenance. Inhaled use for asthma maintenance is typically approved for children 4 years of age and older. Safety and efficacy are not established for children younger than this minimum age. Older adults usually require no specific dose adjustment.

Restrictions and Special Populations

Use requires caution in patients with active or quiescent tuberculous infections of the respiratory tract or other systemic infections. Caution is also advised in cases of severe hepatic impairment due to the potential for increased systemic exposure. Use during pregnancy is not recommended unless the benefit clearly outweighs the potential risk. Fluticasone is generally considered acceptable to use during breastfeeding.

Advertisements

What should I know about interactions with other medicines?

Flohale (Fluticasone) is metabolized through the Cytochrome P450 3A4 (CYP3A4) enzyme system in the liver. Interactions occur when other medicines inhibit this enzyme, which can significantly increase the concentration of Fluticasone in the bloodstream. This increased exposure elevates the risk of systemic corticosteroid effects.

Documented Interacting Agents

The most clinically significant interactions are documented with strong CYP3A4 inhibitors. These agents are generally not recommended for co-administration with Fluticasone unless the potential benefit is determined to outweigh the risk of increased systemic exposure.

Interacting Agent Category Specific Examples Explicitly Listed
Strong CYP3A4 Inhibitors Ritonavir, Ketoconazole, Atazanavir, Itraconazole

Regulatory Constraints

Co-administration with Ritonavir is explicitly documented as not recommended because this combination has been shown to result in a massive increase in Fluticasone systemic levels, leading to post-marketing reports of systemic corticosteroid adverse effects such as Cushing's syndrome and adrenal suppression.

Caution is advised when co-administering Fluticasone with other strong CYP3A4 inhibitors, as the potential for increased exposure and subsequent systemic effects, including adrenal suppression, remains. The systemic burden of Fluticasone should be carefully considered, particularly when other corticosteroid forms are used concurrently.

Advertisements

Mechanism of Action

The mechanism of action for Fluticasone Propionate is entirely rooted in its molecular influence on cellular pathways. Its physiological effects arise from its high-affinity binding to the intracellular Glucocorticoid Receptor (GR), initiating a cascade of genetic modulation.

Genomic Repression of Pro-Inflammatory Signaling

This core mechanistic domain involves transrepression. The Fluticasone-GR complex travels to the cell nucleus where it physically blocks the activity of key transcription factors like NF-kB. This action suppresses the gene transcription required for the synthesis of numerous pro-inflammatory cytokines and chemokines, thereby contributing to the suppression of local inflammation.

Dual Modulation of Mediator Synthesis

The drug simultaneously employs transactivation, upregulating genes that produce proteins, such as Annexin A1, which modulate inflammatory pathways. This protein acts as an indirect inhibitor of the enzyme Phospholipase A2 (PLA2). By blocking PLA2, the mechanism influences dynamics within the eicosanoid pathway by reducing the formation of potent mediators like prostaglandins and leukotrienes.

Resulting Physiological Stabilization

These combined molecular actions lead to direct physiological changes at the tissue level. By reducing inflammatory cell infiltration (e.g., eosinophils and mast cells) and stabilizing local microvasculature, the mechanism influences factors that lead to airway edema (swelling). This sustained biological dampening influences the tissue's responsiveness to stimuli, which is related to the time required for these genomic changes to manifest.

Advertisements

Dosage and Administration Information

The medicine is strictly administered via oral inhalation using specialized devices, such as the Metered-Dose Inhaler (MDI), Dry Powder Inhaler (DPI), or nebulizer suspension. It is intended for daily, continuous use.

Administration Scope

Feature Detail
Route of administration Oral Inhalation only, for localized delivery to the lungs.
Dosing schedule Standard maintenance is twice daily. Adult starting doses for MDI are typically 88 mcg twice daily, with the maximum recommended dose reaching 880 mcg twice daily. Dosing is reduced to the lowest effective level once control is attained.
Age-group rules Pediatric patients (4 years of age and older) are typically initiated on lower strengths. No specific routine dose adjustment is specified for older adults.
Missed-dose rules If a dose is missed, skip the missed dose and take the next dose at the regularly scheduled time; the dose must not be doubled.

Special Procedural Conditions

Standard application sequence:

  • Frequency: The medicine must be used every day on a regular, continuous schedule for its preventative effect. Doses must be separated by approximately 12 hours.
  • Preparation: MDI devices require priming (shaking and spraying) before initial use or after a period of non-use; specific instructions for DPI and nebulizer preparation must be followed.
  • Post-Use Hygiene: Users must rinse the mouth with water and spit it out (not swallow) immediately following each dose.

Connection to the overall use protocol (2–4 sentences): The protocol establishes a fixed, preventative regimen based on the oral inhalation route and a mandatory twice-daily frequency. This protocol requires strict adherence to dose timing and includes a non-negotiable step of post-administration mouth rinsing to ensure correct use. The strategy is defined as long-term maintenance with subsequent dose reduction once therapeutic stability is confirmed.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Flohale (Fluticasone)

Evidence for Use in Persistent Asthma

Fluticasone Propionate was studied in the context of persistent asthma, a long-term condition characterized by fluctuating or episodic manifestations. Research primarily consisted of Randomized Controlled Trials (RCTs) and the reviews that synthesize them. These studies monitored patients to assess outcomes related to outcomes reflecting daily functioning and changes in physiological measurements, such as airflow in the lungs. The observation periods was used in research exploring how symptoms change over time.

Changes in lung function were reported in the observed populations. Research examined patient-reported symptom scores and the frequency of episodes where symptoms become more noticeable. Studies describe patterns observed in the data, but research does not determine whether an individual will respond similarly to the group findings.

Evidence for Chronic Obstructive Pulmonary Disease (COPD)

The role of Fluticasone Propionate was evaluated in long-term clinical trials involving adults with Chronic Obstructive Pulmonary Disease (COPD), a condition marked by functional limitations. These studies were conducted over extended periods, with some research exploring outcomes for two to three years. The core focus was on monitoring the frequency of acute episodes and collecting patient-reported outcomes.

Large trials reported data on the annualized rate of these severe episodes. Researchers also described patterns related to changes in health status scores applied in studies examining patient-reported experiences. However, findings did not establish a consistent pattern regarding the long-term decline of lung function measurements across different patient groups.

What the Research Does Not Fully Characterize

The research landscape highlights several acknowledged gaps where evidence is limited or where further studies are needed. One such area relates to the precise patterns observed for the dose-response relationship for certain dose ranges.

Additionally, the long-term effects are not fully established concerning systemic measurements following continuous use over periods of many years. This evidence provides context regarding what has been researched—and what is still uncertain. Overall, the available research provides context but not individual predictions, meaning the study results reflect the specific conditions under which they were conducted.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Flohale (Fluticasone) (FAQ)

Q: How quickly should I expect Flohale to start working?

A: Official regulatory information indicates that this medicine is designed for long-term control rather than immediate relief. Therefore, the maximum benefit may not be achieved for one to two weeks, or even longer, after you begin using it regularly as directed.

Q: What happens if I stop using Flohale suddenly?

A: The medicine is prescribed for daily, continuous preventative use. Official instructions indicate that stopping it abruptly may lead to the return of your original symptoms. For patients transitioning from oral steroid therapy to an inhaled regimen, official warnings indicate a risk of impaired adrenal function, which requires careful management under supervision.

Q: Is it normal to feel a change in taste after using Flohale?

A: An alteration or loss of the sense of taste, medically known as dysgeusia, has been included in post-marketing reports for Fluticasone products. Regulatory reports include this as a potential experience for some users.

Q: Is Flohale safe to use every day?

A: Official instructions specify that this medicine is intended for continuous daily use on a regular schedule for its preventative effect. However, continuous, long-term use can carry risks of systemic effects, such as adrenal suppression and ocular changes, which are often discussed in official warnings and require careful monitoring.

Q: Does using Flohale affect sleep?

A: Post-marketing experience reports have included some psychiatric and behavioral effects, such as nervousness, restlessness, and irritability. While not a direct sleep medication, these reported effects could potentially have an impact on a user's sleep patterns.

Q: Can Flohale be used long-term?

A: Yes. According to regulatory documents, Fluticasone is specifically indicated for the long-term maintenance treatment of chronic conditions. The official guideline is to use the lowest dosage that successfully keeps the condition under control.

Q: Does alcohol interact with Flohale?

A: Specific warnings for the inhaled form of Fluticasone do not explicitly list an interaction with alcohol. However, some combination products containing Fluticasone may advise caution with concurrent alcohol use due to the potential effects of other active ingredients on the central nervous system.

Q: Can Flohale be used during pregnancy, according to official information?

A: Official regulatory information states that the use of this medicine during pregnancy is not recommended unless the potential benefit to the patient is judged to outweigh any potential risk to the developing fetus. The safety profile has not been definitively established for this use.

Q: Is Flohale safe to use while breastfeeding?

A: Official product information notes that Fluticasone is generally considered acceptable to use during breastfeeding. Regulatory documents state that use is considered after weighing the potential benefit to the mother against the potential risks to the infant.

Q: What does 'systemic absorption' mean in relation to Flohale?

A: Systemic absorption refers to the small amount of medicine that is absorbed into the general bloodstream rather than staying localized in the lungs or nasal passages. Regulatory information indicates that, with correct use, this absorption is generally low but is responsible for the potential risk of systemic corticosteroid side effects.

Q: Is Flohale helpful for non-allergic nasal issues?

A: The medicine is indicated for the regular treatment of symptoms associated with chronic nasal inflammation and conditions like nasal polyps. This suggests it may be used for issues where inflammation is a factor, regardless of whether the inflammation is caused by allergies or not.

Q: Can I use Flohale if I have a history of tuberculosis?

A: Official warnings state that use requires caution in patients with active or quiescent tuberculous infections of the respiratory tract, as well as other systemic infections. This is because corticosteroids can have an immunosuppressive effect.

Q: Is Flohale an anti-histamine?

A: No. Flohale (Fluticasone Propionate) is officially classified as a potent synthetic glucocorticoid (corticosteroid), not an antihistamine. It works by reducing local inflammation through a different mechanism than blocking histamine receptors.

Q: Are there any common foods or drinks that interact with Flohale?

A: Regulatory documents primarily focus on certain prescription medicines, specifically strong CYP3A4 inhibitors, as the main interaction risk. No common foods or drinks are explicitly documented in official product information as clinically significant interacting agents for the inhaled form.

Q: Does Flohale cause weight gain?

A: Weight gain has been reported in post-marketing experience with Fluticasone products. The risk of systemic effects, which can include changes like weight gain, is generally associated with higher doses and prolonged use.

Q: Can Flohale make anxiety or nervousness worse?

A: Anxiety and nervousness are listed among the psychiatric adverse reactions that have been reported with Fluticasone products in post-marketing experience. These effects are primarily observed in children.

Q: Is it possible to become reliant on Flohale?

A: This medicine is a controller medicine intended for daily, continuous use to keep chronic symptoms stable and prevent serious episodes. Using it daily is intended for the maintenance of symptoms, which is distinct from physical reliance.

Q: Is there a generic version of Flohale available?

A: Yes. The active ingredient, Fluticasone Propionate, is available in various generic forms and different brand-name products across numerous international markets, depending on the specific product formulation and delivery device.

Q: Does Flohale contain decongestants?

A: The active ingredient in Flohale is Fluticasone Propionate, which is a corticosteroid. It is not classified as a decongestant. The official product information does not list any decongestant agents in the composition.

Q: Can I use Flohale at the same time as my other allergy medicine?

A: Regulatory guidelines emphasize the need to avoid strong CYP3A4 inhibitor medicines due to interaction risks. Use with most other common allergy medicines, such as antihistamines, is not typically listed as being strictly prohibited.

Q: Is there any evidence about Flohale and its use in older adults?

A: Regulatory information notes that the usual adult dosage is applicable to older adults, and no specific dose adjustment is typically specified. Official information notes that caution is often advised in this population due to the higher potential for age-related impairment of liver, kidney, or heart function.

Q: Does Flohale have an impact on blood sugar levels?

A: Hyperglycemia (high blood sugar) has been reported in post-marketing experience with Fluticasone products. This is a potential systemic effect of corticosteroids, which may require monitoring in patients with diabetes.

Q: What should I do if the Flohale spray does not seem to be working?

A: Official instructions state that if symptoms worsen or do not respond to the dosage after several weeks of continuous use, medical advice should be obtained for re-evaluation of the treatment plan.

Q: Are there different strengths of Flohale available?

A: Yes. Fluticasone Propionate is available in different strengths per actuation (or dose) depending on the specific product and device type. This allows the dose to be adjusted to maintain the lowest effective dose for symptom control.

Q: Is it common to feel dry throat or irritation after using Flohale?

A: Throat soreness, irritation, and dryness have all been reported in post-marketing experience with Fluticasone products. This is classified as a common local adverse reaction.

Q: Does the time of day matter when using Flohale?

A: The dosing schedule is typically twice daily, and the doses must be separated by approximately 12 hours to ensure a continuous preventative effect. The specific time of day is not regulated, provided this 12-hour separation is consistently maintained.

Q: Can Flohale be used before outdoor activities to prevent allergy symptoms?

A: Fluticasone is classified as a preventative medicine intended for continuous, regular daily use. It is not an acute, rapid-acting medicine for immediate relief or for use right before known exposure, as maximum benefit takes one to two weeks to develop.

Q: Does Flohale interact with any common herbal supplements?

A: Official information generally advises caution regarding the use of complementary medicines, herbal remedies, and supplements alongside prescription drugs. There is usually not enough formal information to determine if these products are safe to take with Fluticasone.

Q: What if I accidentally swallow some of the Flohale spray?

A: Official information indicates that the systemic absorption of Fluticasone from the gastrointestinal tract is extremely low. This is due to poor absorption and extensive first-pass metabolism, meaning systemic exposure from accidentally swallowing a dose is considered negligible.

Q: Are there any regulatory warnings about Flohale that I should know?

A: Official warnings include the potential for local infections in the mouth, systemic corticosteroid effects like adrenal suppression, ocular effects such as glaucoma or cataracts, and reduced immune response that can worsen existing infections.

Q: Does Flohale have any known drug interactions with birth control pills?

A: Regulatory information suggests a low likelihood of interaction with hormonal birth control pills. This is based on the finding that Fluticasone has negligible affinity for the estrogen and androgen receptors, but this is not based on direct interaction study data.

Advertisements

How should Flohale (Fluticasone) be stored and disposed of?

How to Store and Dispose of Flohale (Fluticasone)

Official regulatory documentation specifies strict environmental, container, and shelf-life requirements for fluticasone products.

Required Storage Conditions

Fluticasone nasal sprays must be stored between 4 C and 30 C (39 F and 86 F). Inhalation powders are typically stored at Controlled Room Temperature (20 C to 25 C). It is mandatory that the product be stored in a dry place and protected from direct heat, sunlight, and freezing.

Stability and Disposal

The product must be stored out of the sight and reach of children. The in-use shelf life is limited after the original packaging is opened; for example, some inhalation powders must be discarded 6 weeks after opening the foil pouch. Unused or expired medication must be disposed of safely, typically by placing it in the trash, following local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Flohale (Fluticasone) found in:

A-Z Index: